Axolabs
Biotechnology ResearchBavaria, Germany201-500 Employees
Axolabs is a mid-sized biotechnology company specializing in nucleic acid therapeutics, a class of drugs whose active components are derived from DNA or RNA. The company offers a range of services, including oligonucleotide synthesis, analytics, bioinformatics, and in vitro and in vivo analyses, to support clients developing these therapies from early research through preclinical testing. As part of the LGC Group, Axolabs operates under a dedicated brand for nucleic acid therapeutics with sites in Kulmbach and Berlin in Germany and Petaluma in the United States. It serves biotechnology and pharmaceutical companies and research partners pursuing oligonucleotide therapies, helping them advance candidates through development toward clinical trials or approved use. A Berlin GMP manufacturing site is being established to support medium to large-scale clinical manufacturing of nucleic acid therapeutics, with operations scheduled to begin in 2025, and it will provide integrated analytical and manufacturing capabilities alongside the Petaluma facility.
1-888-653-2347 
support@leadiq.com 
